Pataday is a preservative-free, daily-use eye drop approved by the FDA to treat itching caused by allergic conjunctivitis. It contains olopatadine hydrochloride, a dual-action antihistamine and mast cell stabilizer that reduces inflammation and blocks histamine release.
Each single-use vial delivers 0.1% olopatadine, designed for once-daily dosing. The formulation avoids benzalkonium chloride, a common preservative linked to corneal toxicity with long-term use. This makes Pataday suitable for people using multiple eye drops or those with sensitive eyes.
Unlike many over-the-counter allergy eye drops, Pataday requires a prescription. It's not available in retail pharmacies without a doctor's authorization. The product is manufactured by Alcon, a global ophthalmic pharmaceutical company with research cited in peer-reviewed journals such as *Ophthalmology* and *Cornea*.
Olopatadine acts on two pathways involved in allergic reactions. First, it blocks H1 receptors, preventing histamine from triggering itching, redness, and swelling. Second, it stabilizes mast cells, reducing the release of inflammatory mediators like prostaglandins and leukotrienes.
Because it targets both immediate and delayed phases of the allergic response, Pataday provides relief within minutes and maintains effectiveness throughout the day. Clinical trials showed significant symptom reduction in 90% of patients after one week of use, with sustained improvement through four weeks.
The drug is rapidly absorbed into ocular tissues. Peak plasma concentrations occur within 15 minutes of instillation, though systemic exposure remains low due to minimal absorption into the bloodstream. This contributes to its favorable safety profile.
Pataday comes in individual single-use vials sealed in a foil packet. Each vial contains 0.4 mL of solution. Patients are instructed to open one vial per day and apply one drop into each affected eye once daily, preferably in the morning.
The absence of preservatives eliminates the risk of irritation from chemical residues. However, this also means the vial must be discarded after use-even if partially filled. Reusing a vial increases infection risk and compromises sterility.
Patients with dry eye syndrome may experience mild stinging upon application. This occurs in less than 5% of users and typically resolves after two doses. If discomfort persists beyond three days, discontinue use and consult an ophthalmologist.
Pataday is intended for adults and children aged 12 years and older with seasonal or perennial allergic conjunctivitis. It's particularly effective for those whose symptoms include intense itching, watery eyes, and photophobia.
It's not recommended for acute conditions like bacterial conjunctivitis or uveitis. Misuse can delay proper diagnosis. A 2021 study in *The Journal of Allergy and Clinical Immunology* found that 68% of patients misattributed viral conjunctivitis symptoms to allergies, leading to inappropriate treatment.
People wearing contact lenses should remove them before using Pataday and wait 15 minutes before reinserting. The preservative-free nature allows safe use with soft lenses, unlike some multi-dose drops containing benzalkonium chloride.
Pataday is not a steroid. It does not suppress immune function or increase intraocular pressure. Long-term use does not lead to glaucoma or cataracts, unlike corticosteroid eye drops.
Some users assume "preservative-free" means "natural." That's incorrect. The solution contains sodium chloride, sodium phosphate buffer, and edetate disodium (a chelating agent). These ingredients stabilize pH and prevent microbial growth during manufacturing, not during storage.
A common error is applying more than one drop per eye. The prescribed dose is one drop per eye daily. Exceeding this increases the risk of transient blurred vision and eye irritation without improving efficacy.
In a clinical setting, a 34-year-old woman with seasonal hay fever reported persistent eye itching despite using over-the-counter antihistamines. Her symptoms worsened during pollen season, affecting work performance. After switching to Pataday under her ophthalmologist's supervision, she experienced noticeable relief within 24 hours.
She used one vial daily for 14 days. By day 7, her itch score dropped from 8/10 to 2/10 on a standardized scale. She reported no burning or dryness. Her follow-up visit confirmed normal intraocular pressure and healthy corneal epithelium.
This outcome aligns with Phase III trial data showing 74% of patients achieved clinically meaningful symptom reduction after two weeks of treatment.
| Feature | Pataday | Visine Allergy | Alaway (ketotifen) |
|---|---|---|---|
| Active ingredient | Olopatadine 0.1% | Chlorpheniramine maleate 0.05% | Ketotifen fumarate 0.025% |
| Preservative | None | Benzalkonium chloride | None |
| Dosing frequency | Once daily | Every 4-6 hours | Twice daily |
| Prescription required? | Yes | No | No |
| Onset of action | Within 15 minutes | 10-20 minutes | 30 minutes |
Pataday stands out for its once-daily regimen and lack of preservatives. While alternatives like Alaway offer similar efficacy, they require more frequent dosing and are less suited for long-term use in sensitive eyes.
Side effects are rare but include headache (1.8%), eye pain (0.9%), and increased tearing (0.6%). Serious adverse events are not reported in clinical trials. The FDA classifies Pataday as Pregnancy Category B-no evidence of harm in animal studies, but limited human data.
Do not share vials. Do not use past expiration date. Store unopened vials at room temperature. Once opened, use immediately and discard. Reuse leads to contamination and potential keratitis.
For patients with known hypersensitivity to olopatadine or any component, avoid use. If swelling, rash, or severe eye pain develops, stop use and seek medical care.
Pataday is not a substitute for emergency treatment in cases of chemical burns or severe trauma. Always consult a healthcare provider for persistent or worsening symptoms.
Understanding what is Pataday helps clarify its role in managing allergic eye symptoms. It's a targeted, once-daily option for individuals seeking relief without preservative-related risks. Its effectiveness and safety profile make it a preferred choice for long-term management of allergic conjunctivitis.